World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02925702
Date of registration: 29/09/2016
Prospective Registration: No
Primary sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Public title: PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223. PRORADIUM
Scientific title: Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resitant Prostate Cancer Patients Treated With Radium-223.
Date of first enrolment: February 2016
Target sample size: 161
Recruitment status: Active, not recruiting
URL:  https://clinicaltrials.gov/show/NCT02925702
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
Spain
Contacts
Name:     Rafael Morales, MD
Address: 
Telephone:
Email:
Affiliation:  Hospital Vall d'Hebron
Name:     David Olmos, MD
Address: 
Telephone:
Email:
Affiliation:  CNIO-Centro Nacionald e Investigaciones Oncológicas
Name:     Elena Castro, MD
Address: 
Telephone:
Email:
Affiliation:  CNIO-Centro Nacionald e Investigaciones Oncológicas
Name:     Maria Isabel Saez, MD
Address: 
Telephone:
Email:
Affiliation:  Hospital Universitario Virgen de la Victoria
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male age = 18 years

2. Histologically confirmed adenocarcinome of the prostate

3. ECOG Performance Status = 2

4. Castration resistance must be documented with surgical or medical castration with
serum testosterone < 50 ng/mL (< 2.0 nM).

5. Men diagnosed with at least one metastatic lesion on CT or bone scan.

6. Documented biochemical and/or radiographic progression to previous treatment according
to PCWG2 criteria.

7. Patients who are candidates for standard of care treatment with Radium-223 55mBq/Kg
very 4 weeks intravenously

8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy
and/or radical prostatectomy.

9. Acceptable hematological, hepatic and renal functions.

Exclusion Criteria:

1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
and who are five years cancer-free or those diagnosed with skin cancers (of
non-melanoma type) or excised in situ carcinomas.

2. Any condition or reason that, in the opinion of the Investigator, interferes with the
ability of the patient to participate in the trial, which places the patient at undue
risk, or complicates the interpretation of safety data



Age minimum: 18 Years
Age maximum: 99 Years
Gender: Male
Health Condition(s) or Problem(s) studied
Advanced Prostate Cancer
Castration Resistant
Radium 223
Intervention(s)
Drug: Radium 223 55mBq/Kg every 4 weeks intravenously
Primary Outcome(s)
To validate the prognostic value for overall survival of serum bone metabolism markers descibed by Primo N Lara et al (JNCI 2014) in mCRPC patients treated with Radium-223 [Time Frame: Initially 48 months, currently 60 months]
Secondary Outcome(s)
To assess the prognostic value for overall survival of androgen receptor splicing variant 7 (AR-V7) and/or AR amplification in mCRPC patients treated with Radium-223 [Time Frame: Initially 48 months, currently 60 months]
To analyze the prognostic value of "Bone Scan Index" in mCRPC patients treated with Radium-223 [Time Frame: Initially 48 months, currently 60 months]
To analyze the prognostic value for biochemical and/or radiological progression-free survival of serum bone metabolism markers described by Primo N Lara et al in mCRPC patients treated with Radium-223 [Time Frame: Initially 48 months, currently 60 months]
To assess the prognostic value of alkaline phosphatase before- and after 3 cycles of treatment in these patients [Time Frame: Initially 48 months, currently 60 months]
To correlate the presence of somatic and/or germinal mutations with the outcomes of these patients [Time Frame: Initially 48 months, currently 60 months]
To validate the prognostic value of the gene-expression signature from peripheral blood described by Olmos et al (Lancet Oncol 2012) on overall survival of mCRPC patients [Time Frame: Initially 48 months, currently 60 months]
Exploratory aims include: Validate the prognostic value of classical nomograms designed to assess the outcomes of mCRPC patients and analyze the prognostic value of the gene-expression signature described by Olmos et al on progression-free survival. [Time Frame: Initially 48 months, currently 60 months]
Secondary ID(s)
CNI-RAD-2016-01
IBIMA-CNIO-CP-03-2015
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history